Agios Pharmaceuticals Stock (NASDAQ:AGIO)
Previous Close
$44.92
52W Range
$19.80 - $50.35
50D Avg
$45.29
200D Avg
$34.01
Market Cap
$2.66B
Avg Vol (3M)
$523.81K
Beta
0.75
Div Yield
-
AGIO Company Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
Annual
| Product/Service | Dec 23 | Dec 22 | Dec 20 |
|---|---|---|---|
| Product | $26.82M | $11.74M | $121.09M |
| Royalty | - | $2.50M | $10.26M |
| Collaboration Revenue, Related Party | - | - | $68.27M |
| Commercialization Activity | - | - | $3.93M |
| Committee Participation | - | - | - |
| Development Activities | - | - | - |
| Research Services | - | - | $64.35M |
Latest
Fiscal year ends in Dec 23 | Currency in USD
Peer Comparison
| Ticker | Company |
|---|---|
| ANAB | AnaptysBio, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| ARVN | Arvinas, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| KALV | KalVista Pharmaceuticals, Inc. |
| MREO | Mereo BioPharma Group plc |
| BPMC | Blueprint Medicines Corporation |
| DAWN | Day One Biopharmaceuticals, Inc. |
| MGTX | MeiraGTx Holdings plc |
| STOK | Stoke Therapeutics, Inc. |
| BMRN | BioMarin Pharmaceutical Inc. |
| COGT | Cogent Biosciences, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| KROS | Keros Therapeutics, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| MRSN | Mersana Therapeutics, Inc. |
| FIXX | Q32 Bio Inc. |